Navigation Links
Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
Date:1/15/2008

haracteristics of Kosan's product candidates; and the opening or initiation of additional clinical trials and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of Kosan's product candidates, including the risk that studies may not accrue patients on a timely basis, demonstrate safety and efficacy sufficient to design or initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; the costs of conducting preclinical and clinical studies for Kosan's product candidates; Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's dependence upon the formation and sustainability of partnering arrangements and other risks detailed from time to time in the Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb Company


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
4. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
5. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
9. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
10. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
11. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Charlene Vernak, RPh, of Vernak Farms ... recently was awarded the George Roentsch Scholarship by the ... award in Houston during PCCA,s ... awarded annually to an independent pharmacist and PCCA member ... George Roentsch , a well-known pharmacist in the compounding ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... Novavax, Inc. (Nasdaq: NVAX) ... and immunogenicity results from its 2009 H1N1 virus-like particle ... the invitation-only 7th World Health Organization Meeting (WHO) on ... meeting was held at the WHO headquarters in Geneva, ...
... BEIJING, Feb. 18, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, announced its ... December 31, 2010 ("3Q FY2010") today. ... Months EndedDecember 31, 2009December 31, ...
Cached Medicine Technology:NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 2NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 3NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 4NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 2China Medical Technologies Reports Third Fiscal Quarter Financial Results 3China Medical Technologies Reports Third Fiscal Quarter Financial Results 4China Medical Technologies Reports Third Fiscal Quarter Financial Results 5China Medical Technologies Reports Third Fiscal Quarter Financial Results 6China Medical Technologies Reports Third Fiscal Quarter Financial Results 7China Medical Technologies Reports Third Fiscal Quarter Financial Results 8China Medical Technologies Reports Third Fiscal Quarter Financial Results 9China Medical Technologies Reports Third Fiscal Quarter Financial Results 10China Medical Technologies Reports Third Fiscal Quarter Financial Results 11China Medical Technologies Reports Third Fiscal Quarter Financial Results 12China Medical Technologies Reports Third Fiscal Quarter Financial Results 13China Medical Technologies Reports Third Fiscal Quarter Financial Results 14China Medical Technologies Reports Third Fiscal Quarter Financial Results 15China Medical Technologies Reports Third Fiscal Quarter Financial Results 16China Medical Technologies Reports Third Fiscal Quarter Financial Results 17China Medical Technologies Reports Third Fiscal Quarter Financial Results 18China Medical Technologies Reports Third Fiscal Quarter Financial Results 19China Medical Technologies Reports Third Fiscal Quarter Financial Results 20China Medical Technologies Reports Third Fiscal Quarter Financial Results 21China Medical Technologies Reports Third Fiscal Quarter Financial Results 22
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- The United States ... from Ebola-affected nations of West Africa land at ... for infection with the virus. In a ... noted that 94 percent of air passengers from ... one of these five airports -- New York ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 During the ... fresh water supply runs dangerously low, Southern Oregon’s water ... Oregon’s rivers, despite the lowest mountain snow pack on ... late summer and early autumn.* That was the observation ... the new book “Hiking Southern Oregon,” during an interview ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... community for people who support affordable health insurance options for American ... ... 10, 2008 -- While politicians dispense their health care ideas at ... the same online. The common place to do so is at ...
... Forest, NC company specializing in risk assessment for diabetics, recently announced ... Retasure™ solution to provide retinal imaging risk assessment. , ... ... -- Digital Healthcare, a Wake Forest, NC company specializing in ...
... of free clinics is now available on ... that assist with the costs of medicine. The ... and is the most extensive list available in ... addition to NeedyMeds’ already extensive listings of patient ...
... ,Essilor is pursuing its growth strategy in Eastern ... Optix. The company is a leading,operator in the ... total revenue of more than EUR10 million., ... a recognized market,player, the acquisition will enable Essilor ...
... of checkpoint signaling and DNA repair mechanisms to ... branches in the checkpoint response pathwayataxia telangiectasia-mutated (ATM) ... to interact with DNA damage sensing and repair ... circumvent, or exploit various aspects of the DNA ...
... Sept. 9 Brazos Valley residents,neuroscience researchers, and ... internationally recognized researchers on the,topic of stroke during ... Symposium on Sept. 19. This year,s symposium will ... an afternoon session for clinicians,and researchers. The speakers ...
Cached Medicine News:Health News:Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue 2Health News:The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients 2Health News:Urgently Needed Database Now Available for People Who Cannot Afford Health Care at NeedyMeds.com 2Health News:A potential approach to treatment of hepatitis B virus infection 2Health News:Texas Brain and Spine Institute to Hold Second Annual Neuroscience Symposium 2
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
Medicine Products: